ArticleCureus2026
Outcomes of Nucleos(t)ide Analogue Discontinuation in Noncirrhotic Patients With Chronic Hepatitis B: A Retrospective Study.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Finite nucleos(t)ide analogue (NUC) therapy is an emerging treatment strategy in selected patients with chronic hepatitis B (CHB). We evaluated the feasibility, efficacy, and safety of NUC discontinuation in non-cirrhotic patients fulfilling the Asian Pacific Association for the Study of the Liver (APASL) stopping criteria. Methods We retrospectively analysed data from a tertiary gastroenterology clinic (January 2021-December 2024). Consecutive non-cirrhotic CHB patients meeting APASL criteria were included: hepatitis B e-antigen (HBeAg)-positive with stable HBeAg seroconversion and undetectable hepatitis B virus (HBV) DNA ≥12 months (preferably ≥3 years), or HBeAg-negative with ≥2 years of therapy and undetectable HBV DNA on three occasions, six months apart. Exclusion criteria were significant alcohol intake, viral coinfections, extrahepatic HBV disease, personal or family hepatocellular carcinoma (HCC) history, cirrhosis by imaging or elastography, or unwillingness to discontinue therapy. Patients were monitored for two years with clinical assessment, alanine aminotransferase (ALT), and HBV DNA. Retreatment was predefined upon virological or biochemical relapse. Results Twenty-nine patients were included (HBeAg-positive, 15; HBeAg-negative, 14). At three months, virological relapse occurred in 14/29 (48.3%) patients, more frequently in HBeAg-positive than in HBeAg-negative patients (10/15 (66.7%) vs 4/14 (28.6%); p = 0.047). No significant difference in virological relapse was observed between patients receiving tenofovir and those receiving entecavir (ETV) (5/15 (33.28%) vs 9/14 (64.28%); p = 0.09). All relapsed patients restarted the same NUC and achieved complete viral suppression within two years. Sustained off-therapy remission was observed in 15/29 (51.7%), more common in HBeAg-negative than HBeAg-positive patients (10/14 (71.4%) vs 5/15 (33.3%); p = 0.049). No flare, hepatic decompensation, antiviral non-response, or deaths occurred. Conclusions Finite NUC therapy was feasible and safe in non-cirrhotic CHB patients meeting APASL criteria. Sustained remission was maintained in half of the patients, supporting finite therapy with early monitoring and clear retreatment thresholds. However, larger multicentre studies are needed to validate these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.